Peng Li

Dr. Peng Li


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
HYHua Yu
Hua Yu
JQJian-Feng Qiu
Jian-Feng Qiu
LMLi-Juan Ma
Li-Juan Ma
YHYuan-Jia Hu
Yuan-Jia Hu
PLPeng Li
Peng Li
Jian-Bo WanJian-Bo Wan
Jian-Bo Wan

8 June 2021 in Journal of Advanced Research
Verified
Journal Article
Open access
SWSongsong Wang
Songsong Wang
FSFeiya Sheng
Feiya Sheng
LZLiang Zou
Liang Zou
Jianbo XiaoJianbo Xiao
Jianbo Xiao
PLPeng Li
Peng Li
Non-alcoholic fatty liver disease (NAFLD) results from increased hepatic total cholesterol (TC) and total triglyceride (TG) accumulation. In our previous study, we found that rats treated with hyperoside became resistant to hepatic lipid accumulation. The present study aims to investigate the possible mechanisms responsible for the inhibitory effects of hyperoside on the lipid accumulation in the liver tissues of the NAFLD rats. Label-free proteomics and metabolomics targeting at bile acid (BA) metabolism were applied to disclose the mechanisms for hyperoside reducing hepatic lipid accumulation among the NAFLD rats. In response to hyperoside treatment, several proteins related to the fatty acid degradation pathway, cholesterol metabolism pathway, and bile secretion pathway were altered, including ECI1, Acnat2, ApoE, and BSEP, etc. The expression of nuclear receptors (NRs), including farnesoid X receptor (FXR) and liver X receptor α (LXRα), were increased in hyperoside-treated rats’ liver tissue, accompanied by decreased protein expression of catalyzing enzymes in the hepatic de novo lipogenesis and increased protein level of enzymes in the classical and alternative BA synthetic pathway. Liver conjugated BAs were less toxic and more hydrophilic than unconjugated BAs. The BA-targeted metabolomics suggest that hyperoside could decrease the levels of liver unconjugated BAs and increase the levels of liver conjugated BAs. Taken together, the results suggest that hyperoside could improve the condition of NAFLD by regulating the cholesterol metabolism as well as BAs metabolism and excretion. These findings contribute to understanding the mechanisms by which hyperoside lowers the cholesterol and triglyceride in NAFLD rats.

1 June 2017 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YHYichen Hu
Yichen Hu
JZJinming Zhang
Jinming Zhang
LZLiang Zou
Liang Zou
CFChaomei Fu
Chaomei Fu
PLPeng Li
Peng Li
GZGang Zhao
Gang Zhao

1 May 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JMJiang Maoyuan
Jiang Maoyuan
FSFeiya SHENG
Feiya SHENG
ZZZhen Zhang
Zhen Zhang
XMXiao Ma
Xiao Ma
TGTianhui Gao
Tianhui Gao
PLPeng Li
Peng Li

2 December 2013 in Epilepsia
Verified
Journal Article
Closed access
PDF file
HZHui‐Ling Zhu
Hui‐Ling Zhu
Jian-Bo WanJian-Bo Wan
Jian-Bo Wan
YWYi‐Tao Wang
Yi‐Tao Wang
BLBao‐Cai Li
Bao‐Cai Li
CXCheng Xiang
Cheng Xiang
PLPeng Li
Peng Li

1 November 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
KGKumar Ganesan
Kumar Ganesan
YWYan Wang
Yan Wang
FGFEI GAO
FEI GAO
QLQingqing Liu
Qingqing Liu
CZChen Zhang
Chen Zhang
Jiianping ChenJiianping Chen
Jiianping Chen
Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC.